
Opinion|Videos|May 7, 2024
Efficacy and Safety of Aflibercept 8 mg in PULSAR Trial in Neovascular AMD
Author(s)Marion Munk, MD, PhD
Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.
Advertisement
Episodes in this series
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
FLORetina 2025: Fibrosis, a limiting factor in visual acuity outcomes in neovascular AMD
2
FLORetina 2025: Multimodal deep learning for CKD diagnosis using retinal images and urine dipstick data
3
FLORetina 2025: Rajvardhan Azad on bridging global gaps in ROP care
4
FLORetina 2025: Port delivery system shows reliable 6-month durability and sustained efficacy in neovascular AMD for up to 7 years
5














































